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Abstract
Docking and scoring are widely used in nowadays drug discovery process. Scoring
function is used as a fast method to estimate the docking results. In this thesis, a
regional-defined genetic algorithm approach is developed to optimize the force-field
based scoring function.
Human pregnane X receptor (PXR) is a nuclear receptor which is promiscuous in its
affinity for ligands such as bile acid, steroid hormones, fat-soluble vitamins, prescription
and herbal drugs, and environmental chemicals. In this thesis, the development and
validation of in silico three-dimensional models for the pregnane X receptors is presented.
These model aim at the screening of drug candidates for potential activity towards the
PXR.
Potential side effects and toxicity of anti-trypanosomiasic active compounds were
investigated using the VirtualToxLab. This technology identifies the binding mode of a
small-molecule compound toward a series of 16 target proteins (nuclear receptors,
cytochrome P450 enzymes, hERG, AhR) known or suspected to trigger adverse effects. The
kinetic stability of the identified hits are evaluated by molecular dynamics
simulations.
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Chapter 1
Introduction
1.1 Computer Simulation of Protein–Ligand interactions
Protein–ligand interactions play a central role in living cells. From G protein–coupled
signal transduction to nuclear–receptor inducing gene expression, from programming cell
death to embryo stem-cell differentiation. In the era of ever expanding biological
complexity, the interplay between structural, computational and chemical biology has
brought major scientific advances to modern biomedical research. The complexity of
interactions between a small-molecule ligand and its target protein, is often determined
by the flexibility of the protein-binding site and by the structural rearrangements that
occur upon binding. The forces that control protein behavior and their physical–chemical
origins are inferred from equilibrium binding-kinetic measurements or are computed
with molecular models. Calculated energies may be associated with physical and
chemical interactions ruling protein function and behavior. Although in silicomodels are
usually simplified and abstracted from the real world, computational techniques are
continually evolving so as to broaden the range of feasible applications, and the accuracy
of predictions and theoretical approaches are often supportive in guiding and interpreting
experiments.1
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1.1.1 Protein–Ligand Docking
During the docking process, different poses are generated by the search algorithm, which
ideally should sample the degrees of freedom of the protein–ligand complex not
necessarily exhaustive but adequately enough as to include the true binding modes. These
different poses are then evaluated and used to identify the true binding mode(s) for a
given ligand, and to estimate its binding affinity. Hence, a scoring function should not
only be able to ensure a distinction between different alternatives and ranking them
accordingly, but also to represent the thermodynamics of interaction of the protein–ligand
system accurately. Protein flexibility, water molecules and entropy are important factors
that influence docking.
Ligand Flexibility
Ligand conformational sampling is an essential step to generate a multi-conformer
dataset used in ligand sampling (e.g. Glide2). To reduce the complexity of conformational-
space sampling for the ligand and also to collect the binding poses more efficiently,
pharmacophore-based methods have been adopted to pre-align the ligand within the
binding site (e.g. Dolina3), with the underlying algorithm incorporating geometric and
chemical features based on known or computationally– identified template ligands.
Protein Flexibility
Protein flexibility, including side-chain reorientations and backbone motions, can signifi-
cantly modulate the geometry and characteristics of the ligand binding site.4 Due to the
high degrees of freedom, most of the strategies already implemented in protein–ligand
docking programs accounting for side-chain flexibility only, with the inclusion of
backbone flexibility would be computationally extremely demanding.5 Main strategies
including some level of protein flexibility into protein–ligand docking are: (1) soft docking,
allowing a certain overlap between receptor and ligand, limited to small scale
rearrangements associated to side-chain plasticity, without the corresponding backbone
adjustment. (e.g. Glide2); (2) side-chain flexibility, by either systematic exploring
side-chain rotamers or using a stochastic-searching method. (e.g. MedusaDock,6
Cheetah7,8); (3) ensemble docking, implicitly introducing flexibility into protein–ligand
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docking involves the use of an ensemble of protein conformations (X-ray, NMR, molecular
dynamics, Monte Carlo) as a target for docking instead of a single structure (e.g.
AutoDock9); (4) induced-fit docking, consider both side-chain and backbone flexibility
(e.g. IFD,10 RosettaLigand11); (5) molecular-dynamics simulations, generating perturbed
ensembles, which represent ligand-induced binding-site flexibility in a robust
process.12
Watermolecules
Water molecules on the interface of bimolecular complexes play an important role in
protein–ligand interactions13 (hydrophobic interactions, residual mobility, bridged
hydrogen bond, desolvation, dielectric properties). Active-site water molecules can be
considered as an aspect of target flexibility during docking. Properly accounting for
specific water molecules on the interface as well as for the general effect of solvation is a
vital aspect of docking. Rossato et al. developed an algorithm (AcquaAlta8) to match
predicted water positions (structural water molecules) with the Cambridge Structure
Database; Zheng et al. introduced wPMF14 (a knowledge-based method) to predict the
potential hydration sites of protein structure, Abel and Friesner et al. developed
WaterMap15 to identify hydration sites in binding pockets and to evaluate the favorability
of their displacement using an empirical formula based on the computed enthalpic and
entropic contributions, Hu et al. developed WATSite16 to identify hydration sites using a
MD trajectory, the thermodynamic profile of each hydration site is then estimated by
computing the enthalpy and entropy of the water molecule throughout the simulation.
Representation of bulk water is even more problematic than that of specific water
molecules, particularly for polar or charged systems.17 Docking with flexible (on/off)
water molecules (e.g. MolDock,18Cheetah7,8) led to an improvement in pose
prediction.
Entropy
Entropic effects contribute substantially to the protein–ligand binding energy. They arise
from a variety of aspects including the reduction of the translational and rotational
degrees of freedom in the ligand, changes in the normal modes of protein vibration and of
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the ligand during binding, from the arrangement of water layers around the two entities
and even from protonation and deprotonation events. However, in most commonly used
computational applications that deal with protein complexes, including free energy
calculations, entropy is neglected altogether, or dramatic simplified such as counting the
number of ligand rotatable bonds as a factor of ligand entropy. In Cheetah,7,8 the entropic
contribution is estimated from the different conformational flexibility in the bound and
unbound state.
BindingModes—Exploration of the 4th dimension
Figure 1.1: 4D-binding of 17  -estradiol to the Pregnane X receptor
In general, a 3D structures of protein–ligand complex can provide a direct insight into the
interactions between a ligand and its target protein. However, it is hard to discriminate the
favorability of the binding poses. Biographics’ 4D viewer allows inspecting all identified
poses (potential binding modes) Boltzmann-weighted and at once.19 The poses are shown
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with a scaled intensity corresponding to the individual contribution to the binding energy
(cf. Boltzmann weight in the panel at right, figure 1.1). This method could provide a more
meaningful interaction diagram for binding-pose identification.
1.1.2 Scoring functions
Various classes of scoring functions are used for pose prediction and ligand ranking, which
can be classified as physics-based, knowledge-based, empirical-based and
descriptor-based methods.20
Physics-based scoring functions
Physics-based approaches the approximate binding free energy by combining
non-bonded energy terms of molecular-mechanics force fields, solvation energy, with or
without entropy.21 An example is MM-PBSA (Molecular Mechanics Poisson-Boltzmann
Surface Area).22,23 In the MM-PBSA approach, a molecular-mechanics force field
represents the solute (receptor, ligand, and receptor-ligand complex), and the PB equation
represents the solvent molecules as a structureless dielectric continuum with ions
distributed in a mean-field manner according to the Boltzmann distribution. The
dielectric continuum treatment represents the solute as a low dielectric body, with a shape
defined by the atomic coordinates, radii, molecular surface, and its 3D spatial charge
distribution defined by the atomic coordinates and partial atomic charges. The non-polar
solvation is divided into two terms: the repulsive (cavity) and attractive (dispersion)
interactions, which corresponds to the creation of a cavity in water and the vdW
interactions between the non-polar molecule and the water molecules, respectively. The
polar solvation term describes the contribution to the free energy due to polarization of
the solvent environment by the solute. The implicit water model of PB solver neglecting
the degrees of freedom associated with each individual water and ion molecule. The main
equations for the MM-PBSA method are shown below, where G denotes the Gibbs free
energy:
 G =Gsol va t e d [Compl e x ]  (Gsol va t e d [Re c e p t o r ]+Gsol va t e d [Lig and ]) (1.1)
The free energies of each species are typically evaluated by the following relations, where
T is the temperature, S is the entropy, E is the potential energy, evaluated as the terms in
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molecular mechanics force field energy, used in place of the enthalpy:
Gsol va t e d =Ggas +Gsol va t ion  TS (1.2a)
Ggas =Eint e r nal +Ee l e c +EvdW (1.2b)
Eint e r nal =Ebond +Eang l e +Et o r s ion (1.2c)
Gsol va t ion =Esol v,pol a r +Esol v,nonpol a r (1.2d)
The polar solvation energy is obtained by solving the PB equation:
r[✏(r)r (r)] = 4⇡⇢(r) 4⇡ (r)X
i
zi ci e xp ( zi (r)/kBT ) (1.3)
where  (r) is the dielectric constant,  (r) is the electrostatic potential,  (r) is the solute
charge,  (r) is the Stern layer-masking function, zi is the charge of ion type i, ci is the bulk
number density of ion type i far from the solute, kB is the Boltzmann constant, and T is the
temperature; the summation is over all different ion types.
The adoption of the MM-PBSA methodology by the scientific community has resulted in
an increased number of publications including MM-PBSA results, yet it has also seen an
increase in the errors of the predicted binding affinities reported using this method with
respect to the experimentally measured binding affinities. One reason is a net difference
between a large desolvation penalty value and large electrostatic interaction energy could
be very small, but it is that difference strongly affects the binding affinity, a very accurate
determination is required to reduce the errors in the net difference, another reason is in
part to the significant number of parameters in the PB equation that are not optimized by
the end users. The dielectric-interface representation, the interior dielectric constant,
handling of internal cavities, bridged waters are key parameters et to perform a valid
MM-PBSA approach for protein-ligand interactions.24 Advanced methods by
incorporating QM/MM method within the binding pocket to optimize the geometry and
partial charges25 or by using a polarizable force field could give more insight into this
aspect at higher computing expense.
Knowledge-based potentials
Knowledge-based scoring functions are exclusively built from statistical analyses of
experimentally determined complex structures, based on the assumption that interatomic
11
distances occurring more often than some average value should represent favorable
contacts, and vice versa.26 The development from atom-pairwise correlation to group
correlation (network motif, pharmacophore) and incorporation of extended
physical-meaning potentials has optimized this process since its origin. Such as
MotifScore,27 which introduced tally motifs of protein–ligand interaction networks
constructed from experimental structures, it captured frequently occurring protein–ligand
interactions by network motifs instead of pairwise interactions. Another effort captured
knowledge-vested pharmacophore to process a knowledge-guided scoring strategy.
Neudert and Klebe developed DSX,28 consisting of distance-dependent pair potentials,
novel torsion angle potentials and solvent-accessible surface-dependent potentials and
demonstrated good performance in pose prediction and ligand ranking. Zheng et al.14
presented orientation-dependent hydrogen potential. The preceding studies demonstrate
the potential of capturing experimental data for improvement of scoring outcomes,
compared with conventional functions. They also reveal the need for more consistent and
extensive evaluation and comparison.
Empirical scoring functions
The underlying idea of empirical scoring functions is that the binding free energy of a
non-covalent protein–ligand complex can be interpreted as a sum of localized, chemically
intuitive interactions. Such energy decompositions can be a useful tool to understand
binding phenomena. These average functional-group contributions can then be used to
estimate a protein-independent binding energy for a compound that can be compared to
experimental values. If the experimental value is approximately the same as or higher than
the calculated value, one can infer a good fit between receptor and ligand and essentially
all functional groups of the ligand are involved in protein interactions. If the experimental
energy is significantly lower, one can infer that the compound can not fully form its
potential interactions with the protein. Experimental binding affinities have also been
analyzed on a per atom basis in quest of the maximal binding affinity of non-covalent
ligands. Also referred to “empirical scoring functions”, on the other hand, are normally
used to compute the fitness of protein–ligand binding by summing up the contributions of
a number of individual terms, each representing an relevant energetic factor in
protein–ligand binding.29 The weights are assigned by regression technique by fitting
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predicted and experimentally determined affinities to a given set of training complexes
(Böhm and Stahl, 1999). For example, Glide Score:30
GSc o r e =0.05 ·vdW +0.15 ·Coul +Lipo +H bond +Me t a l +Reward s +Ro t B +Si t e (1.4)
GScore designed with an emphasis on recognizing the diversity in protein binding sites by
rewarding or penalizing certain interaction patterns. Of particular interest is the
classification of hydrogen bonds into neutral–neutral, neutral–charged, and
charged–charged types and use of separate terms accounting for “hydrophobic enclosure”
in addition to consideration of hydrophobic contacts between protein and ligand. The
convenience of adding or removing individual terms also makes it possible to develop
customized scoring functions for certain molecular systems to achieve better
performance. On the other hand, adopting intuitive functional forms adds to the
empirical nature of these methods. Empirical scoring functions include only common
protein–ligand interaction patterns. Less common interaction patterns, despite being
strong and specific such as cation- interaction, are usually ignored because they are not
significant in the regression analysis. Or, if a certain factor is not interpretable by human
in a straight- forward manner, such as entropic factors, it is not likely to be included either.
Thus, it is rather difficult, if not impossible, to establish a comprehensive and consistent
description of all possible factors in protein–ligand binding within the framework of an
empirical scoring function.
Machine-learning approaches
One of the postulated weaknesses of scoring resulting in poor affinity prediction, is the
assignment of a common set of weights to the individual functional terms and the
incorrect assumption that these weights are additive in their contribution to binding
affinity. Recent literature has seen an increase of attempts to overcome these
shortcomings by applying machine-learning and nonlinear-regression methods to the
derivation of scoring functions.17 (e.g. eSimDock,31 SFCcoreRF ,32 ID-Score33)
1.1.3 Quantitate Structure–Activity Relationships (QSAR)
QSAR attempt to describe and quantify the correlation between chemical structure and
biological activity. The foundation of quantitative correlations between chemical structure
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and biological effect is the entirely reasonable assumption that the differences in the
physicochemical properties are responsible for the relative potency of the interactions of
the drug with biological macromolecules. It is assumed in the first approximation that
these contribute additively to the affinity of an active substance on its receptor. The
concept of describing the biological activity of substances with mathematical models is
derived from this approach.34 Traditionally, the investigated substances interact with the
same biological target should come from a chemically uniform series and display the
same mode of action. With the advent of 3D-QSAR (CoMFA35), a rational model
representing the binding site could be generated by mapping physico-chemical properties
onto a surface or a grid surrounding the ligand molecules, superimposing in 3D space
(pharmacophore hypothesis), as such a model interacts with all ligands simultaneously, it
represents but an averaged surrogate; a fundamental shortcoming as receptor–ligand
adaptation (the specific alteration of protein conformations induced by the individual
ligand) which leads to different physico-chemical fields experienced by the individual
ligands, cannot be simulated with an averaged model. By introducing pseudo-receptor
concept,36 the Quasar methodology7,37 developed by Vedani et al. is one of the few QSAR
approaches which accounts for ligand triggering induced-fit by specifically allowing for a
topological adaptation of the receptor surrogate to the individual ligand molecules,
solvation effects is also evaluated simultaneously.
1.1.4 VirtualToxLab
The VirtualToxLab38 (VTL) is an in silico tool for predicting the toxic potential (endocrine
and metabolic disruption, some aspects of carcinogenicity and cardiotoxicity) of drugs,
chemicals and natural products. The toxic potential of a given compound is computed by
simulation and quantification of the binding of a small molecule toward a series of 16
proteins known or suspected to trigger adverse effects. Those so-called “off targets”
currently include the androgen, aryl hydrocarbon, estrogen  , estrogen  , glucocorticoid,
liver X, mineralocorticoid, progesterone, thyroid  , thyroid   and peroxisome
proliferator-activated receptor   (PPAR ), potassium voltage-gated channel (hERG) as well
as the enzymes cytochrome CYP450 1A2, 2C9, 2D6 and 3A4.
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Figure 1.2: Pictorial flowchart of the VirtualToxLab19
The underlying technology to quantify the binding affinity (mixed-model QSAR), however,
meets its limitations when attempting to estimate the binding affinity of compounds
significantly different from those present in the training set as individual target proteins
are typically validated using only a few chemical classes (for which affinity data, preferably
determined at a single laboratory, are available). The identification of the binding mode
itself does not depend on any training data as the compounds are docked to the
three-dimensional structure of the target protein.
The binding affinity of a small molecule toward a macromolecular target may be
estimated by generating and quantifying its 4D ensemble both in aqueous solution and at
a target protein and computing the associated changes in the associated energies
therefrom. Here, the term “4D” refers to the consideration of all energetically feasible
poses (potential binding modes, i.e. different positions, orientations and conformations)
of the small molecule, weighted e.g. by a Boltzmann function.
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1.2 Pregnane X Receptor and Drug Metabolism
1.2.1 The Pregnane X receptor
ThepregnaneX receptor (PXR) is anorphannuclear receptor expressed inmammalian liver,
intestine and brain capillaries. It plays a key role in the regulation of both drugmetabolism
and efflux by inducing a network of genes, including those that encode cytochrome P450
enzymes (CYPs, particularly CYP3A4)39 and the multi-drug resistance gene ABCB1, which
encodes the P-glycoprotein.40 Together, these drug-detoxification proteins are responsible
for the elimination of more than 50% of all drugs.41
Figure1.3: Drugs that bind and active PXR, coordinately induce cytochromeP450 isoform3A4 (CYP-
3A4)-mediated drug metabolism and ABCB-1-P-glycoprotein-mediated drug efflux.
The PXR ligand-binding domain (LBD) is highly flexible and largely hydrophobic with five
polar residues capable of both donating and accepting hydrogen bonds. The ligand
binding cavity of PXR is lined with 28 amino acids, with an essentially elliptical shape.42
Because most proteins use shape to dictate specificity, the promiscuity of PXR appears to
be greatly assisted by it’s relatively shapeless binding pocket. Drug candidates that display
agonistic activity toward PXR might cause severe drug–drug interactions and should,
consequently, be removed from the drug-discovery pipeline. PXR has evolved to detect
structurally diverse compounds, resulting in promiscuous protein–ligand interactions.
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Due to the high flexibility of the PXR ligand-binding domain, there were only limited
successes with structure-based modeling approaches to predict PXR activators or
non-activators. Therefore, new theoretical approaches that can effectively characterize the
alterable interaction modes of PXR with its diverse ligands would be in need for solve this
problem.
1.2.2 Approaches in PXRmodeling
Figure 1.4: Top left: the superposed crystal structures of the PXR-LBD, the apo structure is colored
in red(PDB ID 1ILG), the complex structures are colored in green (PDB ID: 1M13, 1NRL, 2O9I, 2QNV,
3R8D, 4NY9, 4XHD). The ligand represented as licorice. Top right: the binding pocket of PXR-LBD
with thepromiscuityhydrophobicbinding site (red lines) andhydrogen-bondacceptor site (red star)
highlighted. Bottom: Chemical structures solved by X-ray binding towards the PXR (PXR/estradiol
was obtained from the author, not available through the PDB).
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PXR has evolved to detect structurally diverse compounds (Figure 1.4), it shows
conformation-change tolerance towards ligand binding. Theoretical approaches that can
effectively characterize the alterable interaction modes of PXR with its diverse ligands are
needed for the analysis and investigation of molecular recognition. A study using
computational solvent mapping43 suggested that Phe288, Trp299 and Tyr306 play an
important role in forming hydrophobic interactions with ligands, and Gln285 is likewise
essential in forming hydrogen-bond interactions with ligands. A comprehensive study
using 3D, 4D and 5D-QSAR methods44 suggested that only a 5D method7 could display
some extend of success for predicting external test set of steroid compounds. Chen et. al.
used multiple binding mode-based quantitative structure-activity relationship
(MBMB-QSAR) method that characterizes the non-bonded interaction profile of human
PXR with its ligands in multiple binding modes. From the predicted models it has been
suggested that the hydrophobic forces and electrostatic interactions play an important
role in hPXR–ligand binding, while the steric factor contributes moderately to the
binding.45 Handa et. al. used MD simulations to sample the active protein conformation
for docking, combined with MM-GB/SA for binding free-energy calculation and found
good correlations,46 which further confirmed the importance of receptor flexibility.
1.2.3 mQSAR for PXR
Figure 1.5: Ligand scaffolds used for the PXR QSAR study
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In this work, affinities (EC50) for PXR binding molecules were selected from a series of
congeneric compounds and classified by chemical type.47–55 The binding modes for the
high affinity representatives in each class are generated by manual docking with Yeti as
well as automated docking with Cheetah and Schrödinger IFD and visually inspected and
identified; the others are docked by both pharmacophore-based pre-aligned docking and
Monte-Carlo metropolis sampling (software Alignator/ Dolina,3 Cheetah7,8) based on the
identified templates. The underlying algorithm particularly allows for two aspects of
ligand–protein binding which would seem to be of utmost importance: 1. Simulation of
induced fit, i.e. allowing the protein to adapt its shape to the different orientations and
conformations of the small molecule during the search procedure and 2. Quantification of
solvent effects (ligand desolvation, solvent stripping). The minimization algorithm is
driven by a directional force field, which has been tailored for simulating hydrogen bonds
and metal-ligand interactions, including ligand polarization terms, and to allow for
dynamic solvation (switch off the water molecules occupying the ligand position in situ) of
the binding pocket as well as for the evaluation of hydrogen-bond and hydrophobic
saturation.7,37 The poses were scored and weighted by means of the 4D viewer.
For the binding poses of the most high-affinity ligands in each class, the kinetic stability
and alternative binding modes are challenged by MD simulations. The binding modes of
the seed compounds were generated based on these confirmed templates. Next, all
energetically feasible binding modes were extracted and used as input for the mQSAR
software Quasar and Raptor.56(Figure 3.24)
Figure 1.6: PXR QSAR process
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1.3 Evaluation of the toxic potential of natural products with
anti-trypanosomal activity
1.3.1 Human African trypanosomiasis
Human African Trypanosomiasis (HAT, or “sleeping sickness”) is a fatal disease caused by
two distinct subspecies of T. brucei (T. b. gambiense and T. b. rhodesiense) transmitted by
the bite of the Tsetse fly (Glossina spp., family Glossinidae) in Africa.57 The clinical
manifestations of this disease depend on the stage of infection and also on the subspecies
of the parasite. After the bite of an infected fly, the parasite multiplies in the lymph and
blood, causing headaches, fever, malaise, weakness, weight loss, arthralgia, and eventually
vomiting and skin lesions. In the latter stages, the parasite crosses the blood-brain barrier,
migrates to the CNS and the cerebral spinal fluid, and causes severe neurological and
psychiatric disorders, leading to death. According to the WHO, around 60 million people
are at risk to contract the sleeping sickness, and T. b. gambiense accounts for more than
90% of the disease.
Figure 1.7: Lifecycle of the African trypanosome, image from CDC58
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According to the WHO, around 60 million people are at risk to contract the sleeping
sickness, and T. b. gambiense accounts for more than 90% of the disease, which is one of
the very few infectious diseases with a mortality rate of 100% if untreated. Currently four
drugs are registered for the treatment of sleeping sickness. It usually managed with a
combination of suramin (T. b. rhodesiense) and pentamidine (T. b. gambiense) for the first
stage of the disease, prior to CNS involvement, being easier to administer. Eflornithine (T.
b. gambiense) and melarsoprol (for both T. b.) are used in the latter stage of the disease
and must cross the blood-brain barrier to reach the parasite, being very toxic and
complicated to administer. Suramin, pentamidine, and melarsoprol have unknown
mechanism of action, while eflornithine inhibits the enzyme ornithine descaboxylase,
involved in the biosynthesis of polyamines required for cell growth. Although these drugs
provide the cure of the infection in some cases, they show serious side effects, such as
nausea, vomiting, fatigue, renal toxicity, neurological complications (suramin),
hypoglycemia (pentamidine), fever, infections, hypertension, diarrhea, and neutropenia
(eflornithine).
In the last decade, the screening of more than 700 new and existing nitro-heterocycles led
the DNDi to find the fexinidazole with potential to treat advanced-stage sleeping sickness.
It is the first new clinical drug candidate in 30 years and after preclinical studies entered as
oral treatment in human phase I studies in September 2009.
1.3.2 Natural products active for T. b. gambiense
Considering the severe disadvantages of the existing drugs, there is a clear and pressing
need for the development of safer andmore effective drugs for the treatment of HAT. Many
natural products have been reported to show antitrypanocidal activity, including
flavonoids, xanthones, lignans, terpenes, and alkaloids. Hamburger et al. recently iden-
tified several classes of natural products with antitrypanosomal activity.59–67 These
compounds represent a diverse and challenging class of chemicals for in silico profiling
against adverse effects.
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Figure 1.8: representative natural-product scaffolds yield HAT activity
1.3.3 In silico toxic potential profiling by the VTL
The toxic potential of these compounds was estimated employing the VirtualToxLab,38
which simulates and quantifies the binding of a given compound against 16 target
proteins known or suspected to trigger adverse effects. As the technology is based solely
on thermodynamic considerations, the resulting protein–ligand complexes were
subsequently challenged by MD simulations employing AMBER,68 which allowed probing
the kinetic stability of the complexes. If stable, a potential side-effect is likely to occur and
the compound could be removed from evaluation pipeline in an early stage of drug
development.
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Chapter 2
Methods
2.1 4D scoring function development
The philosophy of our modeling efforts to quantify the changes in the free energy
associated with small–molecule binding to protein targets is a “mixed-model approach”
combined with multi-dimensional QSAR (mQSAR) based on a directional force field. In
this approach, feasible binding modes of the small molecule at the protein are sampled
using a Monte-Carlo search protocol at the three-dimensional structure of the
macromolecular target and comprised into a 4D data set. As the errors associated with
energy components extracted from such an entity are larger than the differences in free
energies of ligand binding between two related molecules. An afterwards re-scoring
process is needed to re-weight the energy components in order to fit binding energy to the
experimental data. Such a re-weighted receptor environment should be feasible to
generate a quasi-atomistic receptor model for binding affinity prediction.
For all binding modes identified by Cheetah (12 poses/ligand), the following quantities
were calculated: protein–ligand interaction energy, ligand desolvation energy, ligand
entropy and induced-fit energy (Eligand-receptor, Eligand desolvation, T S and Einduced fit,
respectively). Therefrom the binding energy was calculated according to the
equation:
Eb ind ing =El ig and r e c e p t o r  El ig and d e so l va t ion  El ig and s t r a in  T S Einduc e d f i t
El i g and r e c e p t o r =Ee l e c t r o s t a t i c +Evan d e r Waal s +Ehy d r og e n bond ing +Epol a r i za t i on
(2.1)
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The ligand–protein interaction energy was calculated by the Yeti force field:
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For the 12 docking poses to each ligand, Cheetah records the per-residue interaction
energy (with both protein and explicit solvent) for each pose by electrostatic, van der
Waals, hydrogen-bond and polarization energy contributions as Eele, Evdw, Ehbd and Epol.
In order to optimize the parameters, current common trait in the free-energy functions
comprised a linear combination of terms/descriptors adopted from other scoring
functions or force field, with linear weighting coefficients derived by fitting to a training
set of complexes with known structure and affinity, such as gCOMBINE and NeoScore.
However, these protocols do not take alternative poses (multiple conformations) into
consideration for the ligands, which potentially oversimplified the binding process. In the
meanwhile, the interaction energy is mainly contributed by residues within the binding
pocket. Generally, the energy contribution from the protein residues could be
decomposed into van der Waals interaction, hydrogen bond, electrostatic interaction and
polarization energies. These fractions are equally weighted among residues and combined
to yield the protein–ligand binding energy, nevertheless, the local environments within
the binding pocket are not identical between amino acids. For example, a cooperative
hydrophobic effect contributes stronger than isolated ones, the less frequent side-chain
rotamers have a reduced contribution than more frequent rotamers. Weighting factors
should not be identical among different residues. In order to optimize the weighting
factors for each residue, coefficients of each residue-related component were optimized
by a genetic algorithm, the re-weighted sum combined with Eint was regarded as
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Eligand-receptor, the contribution of Eligand-receptor,  Gsolv and T S were optimized by
multiple-linear regression. Furthermore, the QSAR model is a quasi-atomic surrogate
concreted in the binding site, the binding energy components are distance-dependent,
energy contribution by residues far from the binding site are neglected, so only
contributions of residues within the binding pocket are considered for the binding.
Figure 2.1: Region-defined interaction energy calculation
Genetic algorithms (GAs) are iterative optimization techniques inspired by the natural
evolutionary process associated with passing genetic material from parents to their
offspring. The basic idea is to randomly generate an initial population, whose members
(genes) are candidate solutions to the problem (here: a combination of coefficients for all
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energy components within the binding site), and evolve that population (crossover and
mutation) under appropriate selection pressure — a fitness function, to obtain a better
solution. The process starts by representing the search domain by chromosomes that can
be mutated and altered.
The least-squares fitting (used as the fitness function), a mathematical procedure for
finding the best-fitting curve to a given set of points by minimizing the sum of the squares
of the offsets, the coefficient  (4⇥1 matrix) for El ig r e c ,  Gsol v , T S and the slope, is
generated by:
  = (X T ·X ) 1 ·X T ·E Te xp (2.3)
X is a n⇥3matrix, n stands for the number of ligands, 3 stands for the 3 energy components:
El ig r e c , Gsol v and T S. Therein, the r 2 was represented by:
r 2=⌃(Ecali   E¯e xp )2/⌃(Ee xpi   E¯e xp )2 (2.4)
Each gene was components by random numbers between 0.001 and 2.0. For each
optimization step, 1,000 genes were randomly generated and the r2 was calculate and
sorted. The top 50 genes were then selected for crossover. If the crossover operation yield
a better result, then the new gene was inherited, otherwise the original gene was kept for
the next selection round. Crossover and mutation were iteratively performed. If the r2
doesn’t yield better result for 10 iterations, the highest-deviation ligand was referred to as
an outlier and removed.
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2.2 QSAR model for the PXR
In order to predict the ligand binding affinity toward the PXR, a combination of methods
were used to generate the stable ligand binding poses, calculating the binding energies, as
well as fitting the results into a QSARmodel. Themodeling flowchart is illustrated in Figure
2.2:
Figure 2.2: The PXRmodeling flowchart
2.2.1 Protein processing
PXR can bind various kinds of ligands. In order to consider the pre-organization or ligand
induced-fit effect within the binding pocket, multiple crystal structures were used to
enrich the side-chain rotamer library within the binding pocket explicitly. The
three-dimensional complex structures of the human pregnane X receptor ligand binding
domain (hPXR-LBD) were obtained from the Protein Data Bank, with one additional
complex (PXR/17 -estradiol,69 not yet deposited with the PDB) was kindly provided by
Prof. Redinbo (University of North Carolina), here referred to as PXE2. The PDB structures
employed in this project are listed in Table 2.1:
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PDB ID Ligand ID res(Å) Description
1M13 HYF 2.15 hPXR-LBD with hyperforin
1NRL SRL 2.00 hPXR-LBD in complex with SRC-1 and SR12813
2O9I 444 2.80 hPXR-LBD in complex with SRC-1 and T091317
3R8D PNU 2.80 hPXR-LBD with PNU-142721
4NY9 2Q4 2.80 hPXR-LBD with ligand 2Q4
4XHD 40U 2.40 hPXR-LBD with ligand 40U
PXE2 EST 2.65 hPXR-LBD with estradiol
Table 2.1: PDB structures used for PXR docking, SRC-1: steroid receptor coactivator-1
In general, all systems were pre-processed using Maestro’s Protein Preparation Wizard:
missing side chains were completed by Prime; the bond orders were automatically
assigned and hydrogens were added accordingly; alternative locations were removed by
comparing the positions with the other PDB structures; the ligand’s ionization and
tautomeric states were generated by Epik; the hydrogen-bond network were optimized on
the basis of neighboring partners by flip the alternative position of His, Gln and Asn as the
X-ray diffraction data for protein could not distinguish the atom type, the hydroxyl group
directions were also optimized accordingly; Finally two restraint minimization step were
performed to minimize the structure and remove strain: first by fix all the heavy atoms,
then by converging heavy atoms to an RMSD of 0.15 Å. All the crystal waters were included
in the process.
After the automatic optimization procedure, the system were further optimized by Yeti,
which features a directional hydrogen-bond force field to optimize the hydrogen bonds
(equation 2.2), a solvation protocol to solvate the hydrogen bond donor/acceptor site, as
well as various refinement protocols to optimize the side chain orientations
individually.
2.2.2 Docking protocol
The ligands were grouped by chemical classes and for each class the most active
compound was manually docked into the binding site and minimized with Yeti. The
minimization of the complex was performed over two steps: first, only the protein around
28
the ligand (within a distance of 8 Å) was minimized, then the ligand and the protein within
the same zone were optimized. An automated pharmacophore-based, flexible-docking
procedure was performed with the packages (MacroModel, AMSOL, Aquarius,
Alignator/Dolina, Cheetah, BzScore) and analyzed with VTLViewer4D. The automated
docking protocol is illustrated in figure 2.3.
Figure 2.3: The pharmacophore-based, flexible-docking protocol
First the ligand was prepared and minimized with BioX, the solvated template
protein-ligand complex was generated first by orient solute the binding pocket (no ligand)
with Yeti, then added the template ligand back into the solvated protein. The ligand
conformation was sampled by MacroModel and the according solvation energy was
calculated by Aquarius, the ligand atom partial charges (CM1) were generated by AMSOL.
The charged-ligand conformations were then aligning to the template’s pharmacophores
in the binding pocket by Dolina and refined as well as sampled by Cheetah, including
dynamic solvation; at last the generated binding poses were sorted by the Boltzmann-
weighted binding energy and the generated 4D binding poses were employed
further.
In order to consider the main chain flexibility, as well as using an alternative docking
procedure, the induced-fit docking (IFD) protocol was also performed to generate putative
binding modes. To perform IFD designed by Schrödinger, all the water molecules were
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removed from the system. The extended sampling protocol was used which could
generate up to 80 poses using automatic docking settings, the IFD docking poses were
ranked by IFDscore, which accounts for both the protein–ligand interaction energy
(Coulomb term reweighed) and the system energy.
I F D s c o r e =P r ime _e ne r g y +9.057 ·G l id eSc o r e +1.428 ·G l id e _Ecoul (2.5)
The more negative the IFDscore, the more favorable the binding. The top 15% docking
poses were visually analyzed by checking: 1. atom clash; 2. ligand intra-action; 3.
hydrophobic/hydrophilic saturation; 4. hydrogen bond with the key residues (Ser247,
Asn285, His324, His407, Arg410); 5. ⇡-⇡ stacking with the aromatic hydrophobic pore
(Phe288, Trp299, Tyr306). The confirmed poses were selected for MD simulations.
2.2.3 Molecular-Dynamics Simulations
To analyze the interactions between PXR and its ligands from a dynamic point of view,
molecular-dynamics simulations of protein–ligand complexes were performed. For
ligands no crystal structures are available in the PDB, the binding modes obtained by
manual docking as well as selected posed from automatic docking were both taken into
consideration. MD simulations and in particular the analysis of the trajectories allowed for
a more dynamic characterization of the protein–ligand interactions responsible for ligand
binding and to gain insight into the binding mode(s). TheMD simulation flowchart:
Figure 2.4: TheMD simulation equilibration and production flowchart
All MD simulations were performed using the AMBER12 package and corresponding
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all-atom potential function ff99SB-ILDN. The GAFF force field was used to model the
ligands, and the atomic partial charges were determined with Gaussian09 at the
RHF/6-31G* level and fitted by RESP. A 2 fs time step and a 9 Å cutoff value were used for
truncation of non-bonded interactions. Simulation structures were solvated in an
orthorhombic TIP3P water box with periodic boundary conditions at a minimum distance
of 10 Å in each dimension from the solute. Counter-ions (Na+ or Cl ) were added to
neutralize the systems. The particle-mesh Ewald (PME) summation method was adopted
to treat long-range electrostatic interactions. The SHAKE algorithm was used to constrain
all covalent bonds involving hydrogen atoms. Energy minimization was performed in two
stages, with each stage employing 250 steps of steepest decent followed by 750 steps of
conjugate gradient method using position restraints for the solute, the harmonic restraint
weight was set at 25 kcal/mol and 5 kcal/mol for the first and the subsequent
minimization step, respectively; following minimization, 40 ps of MD simulation was
performed to heat the system from 100K to 300K followed with 10 ps equilibration in a
NVT ensemble, the harmonic restraint weight was set at 5 kcal/mol; then the system was
switched to NPT ensemble and equilibrated for 50 ps; after the initial equilibration, the
system was changed back to NVT and equilibrated for another 6 stages (50 ps each) by
gradually reducing the restraint weight of solute from 5 kcal/mol to zero. The production
phase was performed at constant temperature (300K) and constant volume for at least 5.0
ns.
2.2.4 Trajectory analysis
For the MD trajectories, the ligand movement was recorded as the most important criteria
for binding stability. A stable binding mode should have smaller movement compared
with unstable ones during the simulations. Besides the geometric evaluation for
protein–ligand interactions, conserved binding free energy is another criteria for binding
stability. Hydrogen bond distances and angles, binding free energy contributions of
residues in the binding pocket were also recorded for binding-stability check, Based on the
results of trajectory analysis. The confirmed “stable” binding poses were used for
template-based docking of the remaining compounds in each class.
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2.2.5 QSAR studies: Quasar & Raptor
The software Quasar and Raptor were used to generate receptor models for the PXR. The
ligand alignment obtained from the MD-confirmed docking and template-based docking
results was used as input to build the QSAR model. The data set was split into a training
set, used to build the model, and test set, used to evaluate it, in such a way that a maximal
diversity of the training set with respect to binding affinity and chemical properties was
obtained. In order to achieve this goal, the compounds were grouped according to their
chemical class (i.e. sharing the same scaffold) and were ranked by affinity. For each group,
the most and the least active compound was assigned to the training set. From the
compounds remaining in the pool, compounds with different scaffolds and functionalities
were selected to be part of the training set in order to achieve maximal chemical diversity.
For the QSAR simulations, a 4:1 ratio for the training and test set.
In order to develop a model, the ligand alignment along with were added the experimental
binding affinities, the solvation energies, the entropy values and the internal strain as
calculated byMacroModel, were employed as input for the binding affinity.
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2.3 Toxic potential estimation by means of the VTL and MD
simulations
In the VirtualToxLab, the toxic potential of a compound is estimated by simulating and
quantifying its interactions towards a series of macromolecular targets at the molecular
level using automated flexible docking combined with 4D Boltzmann scoring.38 The
technical flowchart of VirtualToxLabTM is presented in Figure 2.5. For the
anti-trypanosomal compounds identified by Hamburger et al. and their metabolites, the
binding affinity towards the 16 targets were estimated by the automatic procedure.
Figure 2.5: The technical flowchart of VirtualToxLab19
In order to provide a reliable in silico affinity estimation, the identified high-affinity
docking poses generated by VTL were visually checked. For each identified high-affinity
pose, the kinetic stability was challenged by MD simulations with the AMBER12 package
(with a minimum of 5 ns production stage).
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Figure 2.6: VirtualToxLab: decision tree for the verification of a prediction (binding mode, affinity,
toxic potential). TP: toxic potential; MD: molecular-dynamics simulation, PP: physico-chemical
properties, ADME: adsorption, distribution, metabolism and elimination properties, consensus
scoring (CS) using other in silico approaches.19
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Chapter 3
Results & Discussion
3.1 Scoring Function development
3.1.1 Flowchart of data processing
Figure 3.1: Left: per-residue binding energy for the whole dataset. Right: binding pocket.
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The r2 value obtained from multiple-linear regression was used as the fitness-function in
the optimization algorithm, which aims at minimizing the least-square deviation between
calculated and experimental binding affinities. The results are shown in fig. 3.2. The
androgen (r2=0.82), estrogen   (r2=0.79) and liver-X receptor (r2=0.68) yield the highest
agreement among the 16 target proteins. For the cytochrome P450 enzymes, CYP3A4
(r2=0.58) and CYP1A2 yield moderate r2=0.58), CYP2D6 and CYP2C9 are poorly fitted
(r2=0.02, 0.19). The latter may be due to the fact that the experimental Kr2 value spawns
only two orders of magnitude which is not truly discriminative. The aryl hydrocarbon
receptor, estrogen receptor  , mineralocorticoid receptor, progesterone receptor, the
hERG ion channel and PPAR  all yield moderate results (r2=0.49, 0.35, 0.49, 0.57 and 0.37),
while the glucocorticoid and thyroid receptor  /  (r2=0.32, 0.20, 0.23) did not fit well at
this point.
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Figure3.2: Fitting results for the 16 target proteins. Experimental values are shownon thehorizontal
axis, calculated values on the vertical axis. Dashed lines are drawn at a factor of 5.0 and 10.0 off the
experimental value.
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3.2 QSAR model development for the PXR
3.2.1 Binding-site analysis
All available X-ray crystal structures of the PXR share a similar backbone conformation.
For the structures with a bound small molecule and/or a co-factor, the main-chain C 
RMSD values are lower than 0.4 Å compared with the highest-resolution structure (1NRL,
resolution 2.0 Å). Consequently, employing a single backbone conformation should be
acceptable for the docking studies. On the other hand, the loop defined by Cys207–Val211
displays major deviations in position and further induces a drift in its adjacent  2 helix,
inside of which the backbone of Asp205 acts as hydrogen bond acceptor to 17 -estradiol
(the bound ligand in the PXE2 structure). This change impedes docking 17 -estradiol to
the PXR when using the protein coordinates of 1NRL. Alternatively, by adapting the  2
helix from PXE2 to 1NRL (fig. 3.3A) and followed with energy minimization, the optimized
structure could adopt similar binding modes for 17 -estradiol as well as most of the other
PXR ligands available in crystal structures by interactive docking with YetiX (fig. 3.4).
A
B
C
Figure 3.3: A: Hybrid structure of the PXR backbone. The 1NRL portion show in blue, the PXE2 part
in red. B and C: His407 act as hydrogen-bond donor (B) and acceptor (C).
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After optimizing the hydrogen-bond network byMaestro’s Protein Preparation Wizard and
the software YetiX: His168, His242, His359, His386 and His418 were protonated at the N ;
His327 and His336 were protonated at the N  according to the potential hydrogen bonds
with the local environment. In the binding pocket, His407 can act as both H-bond donor
(N : 1M13, 1NRL) andH-bond acceptor (N : 2O9I, 4NYL, 4XHD), therefore only the N  was
protonated (figs. 3.3B and 3.3C).
A B C
D E F
Figure 3.4: Superimposed ligands of the crystal structure (carbon atoms colored in pink) and
of the docked poses (carbon atoms colored in grey) with optimized structure. A: 17 -estradiol,
B: SRL12813, C: T091317, D: PNU142721, E: 2Q4 (N-(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-
3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl-3-hydroxy-3-methylbutanamide), F: 40U
(N-(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-
2-yl-2- cyclopropylacetamide).
3.2.2 MD simulation for the PXRwith ligands in the PDB
To analyze the interactions between the PXR and its ligands available in the PDB from a
dynamic point of view, and to profile the key residues within the binding pocket, MD
simulations of protein–ligand complexes followed with trajectory analysis were
performed. A total of four ligands were chosen to comprise representative subset of the
studied PXR complexes: 17 -estradiol, T091317, PNU142721 and 2Q4 (SRL12813 is not
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selected as there is no similar ligands with reported binding affinity to the PXR, 40U is not
selected because it is quite similar to 2Q4). As starting point for the MD studies, for each
ligand the binding mode obtained by manual docking with YetiX was considered. Details
of the simulation protocols are reported in the section 2.2.3, in addition, water molecules
which are important in the binding pocket were restrained during the equilibration
stage.
17 -estradiol
In the complex of 17 -estradiol with the PXR (fig. 3.4A), the hydroxyl group in D-ring
(fig. 3.5) engages two hydrogen bonds with the backbone-carbonyl group of Asp205 and
the side-chain of Arg410 respectively, the oxygen atom on the hydroxyl group of A-ring is
involved in a hydrogen bond with Ser247. Upon challenging the binding by 50.0 ns MD
simulation: the ligand RMSD remained within 1.5 Å throughout the simulation (fig. 3.6A),
the two hydrogen bonds of the ligand with Asp205 and Arg410 are partly retained, the
hydrogen bond between the oxygen atom on A-ring’s hydroxyl group and Ser247 was lost.
Instead, the hydrogen atom on the same hydroxyl group engaged a new hydrogen bond
with Ser247, and Ser247 was further stabilized by a hydrogen bond with Met243. The
MM-PBSA results indicate that the three hydrogen-bonding residues are the main
contributors for the binding free energy (fig. 3.6C). These findings suggest that the docking
pose is kinetically stable and Asp205, Arg410 and Ser247 are the key residues for the
binding.
Figure 3.5: Details of 17 -estradiol binding to the PXR. Left: docking pose; right: MD snapshot.
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Figure 3.6: A: Ligand RMSD 17 -estradiol to the PXR. B: Key-residue hydrogen bond distances for
17 -estradiol with the PXR. C: Binding-energy decomposition within the binding pocket and time-
resolved details for key amino-acid residues of the PXR binding with 17 -estradiol.
T091317
In the complex of T091317 with the PXR, the ligand’s hydroxyl group is stabilized by
engaging a hydrogen bond with His407, the sulfonyl group is stabilized by a hydrogen
bond with Gln285 (which is further stabilized by His327), the sulfonyl-benzyl group is
accommodated by the hydrophobic pocket formed by Phe288–Trp299–Tyr306. Upon
challenging the binding by a 50.0 ns MD simulation, the two hydrogen bonds are retained
in 85% of the time. The ligand RMSD is within 2.0 Å. The results suggest that the docking
pose is kinetically stable, Gln285 and His407 turned out to be key residues for the binding,
the Phe288–Trp299–Tyr306 pocket is important for hydrophobic interactions (especially
for ⇡-⇡ stacking).
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Figure 3.7: A: Details of T091317 binding to the PXR. Left: docking pose; right: the last MD frame. B:
Ligand RMSD. C: Key-residue hydrogen bond distances. D: Binding-energy decomposition within
the binding pocket and time-resolved details for key amino-acid residues.
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PNU142721
In the complex of PNU142721with the PXR (fig. 3.7A): the furo[2,3-c]pyridine part features
hydrophobic interactions with the pocket Phe288–Trp299–Tyr306, the nitrogen atom on
the furo[2,3-c]pyridine part engages a hydrogen bond with Gln285. In contrast, there is no
specific interactions with the pyrimidine part, which contains higher b-factors in the PDB
and refers to weaker stabilization by the protein. After challenging the binding by 50.0 ns
MD simulation: the RMSD values of the furo[2,3-c]pyridine part retains within 1.5 Å
throughout the simulation (fig. 3.8B), the pyrimidin part rotated its direction and engaged
a second hydrogen bond with the backbone of Ser208. The hydrogen-bond distance
between the ligand and Gln285 is retained (fig. 3.9A), which is similar to T091317. The
MM-PBSA results suggest that Gln285, Met243, Phe288 and Tyr306 are the key
contributors for the binding free energy (fig. 3.9B).
A
B
Figure 3.8: A: details of PNU142721 binding to the PXR. Left: docking pose; right: MD snapshot. B:
ligand RMSD of PNU142721 to the PXR.
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AB
Figure 3.9: A: key-residue hydrogen bond distances. B: binding-energy decomposition within the
binding pocket and time-resolved details for key amino-acid residues.
2Q4
In the complex of 2Q4 with the PXR, the hydroxyl group on the 6-membered ring engages
a hydrogen bond with His407, the carbonyl group linking to the 6-membered ring is
involved in another hydrogen bond with Gln285. After challenging the binding by 50.0 ns
MD simulation: the ligand RMSD is within 2.0 Å throughout the MD simulation, the two
hydrogen-bond distances are retained and His407 is the residue contributes most to the
binding free-energy. The docking pose is kinetically stable.
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AB
C
D
Figure 3.10: A: Ligand RMSD of 2Q4 to the PXR. Left: docking pose; right: MD snapshot. B: Key-
residue hydrogen bond distances for 2Q4 with the PXR. C: Binding-energy decomposition within
the binding pocket and time-resolved details for key amino-acid residues of the PXR binding with
2Q4.
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3.2.3 Retrieval of the binding affinity data
Thepharmacological data for the 101 PXR-binding compoundswas obtained frommultiple
sources. The experimental EC50 values range from 0.71 nM to 72.4 µM. The majority of
affinities, however, lies within two orders of magnitude (10-6–10-4M, fig. 3.11). EC50 values
were converted in Ki values for the binding-energy calculation.
Figure 3.11: Distribution of pEC50 values: 77% of the affinities cluster within two logarithmic units,
while the whole data set spans six orders of magnitude (0.71 nM–72.4 µM)
The ligands comprise seven different chemical classes (fig. 3.12), three of which (E, T, S)
have crystal structures deposited with the PDB.
Figure 3.12: Eight classes of compounds used in the QSAR study. All 101 structures are given in
Appendix A.
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3.2.4 Docking to the PXR
In order to obtain realistic binding mode(s) towards the PXR, a combination of protocols
was adopted for the docking process. First, the ligand binding modes from known
structures (in PDB) and their respect stable state after the MD simulation were used as
templates for derivative compounds to be docked interactively with YetiX. Then, the
remaining ligands were assigned to one class each and several automated docking
protocols (AutoDock/Cheetah, Schrödinger’s QPLD and IFD) were used to sample and
rank the potential bindingmodes, the ligand conformation compiled from the first step on
was used as boundary criteria for the selection of potential binding mode(s), relevant
hydrogen bonds and hydrophobic interactions with the Phe288–Trp299–Tyr306 pocket
were considered as key factors to select the most potentially correct binding mode(s).
Finally, the identified stable binding mode(s) of the representative compounds were used
as templates for their respect derivate ligands and interactive docked with YetiX.
Crystal structure-based docking
For compounds which contain derivative structures bound to the PXR in the PDB,
interactive template-based docking was performed, wherein the binding modes from both
the crystal structure and the MD simulations were employed as templates. Protein
structures with different bound ligands were superposed to the hybrid protein and its
side-chain residues within the binding pocket were interactively adjusted to adapt to the
very ligand in crystal structures or MD frames. For each ligand, the geometry was
optimized by MacroModel and atomic partial charges were calculated with AMSOL. The
ligands in each class were automatically superposed to their templates and interactively
docked to their respect optimized form of the hybrid protein (Symposar and YetiX).
E02–E11 share a common ring scaffold with E01 (17 -estradiol). The crystal structure and
MD/MM-PBSA results of the PXR-E01 complex suggest that key hydrogen-bonding
residues (Ser247, Arg410 and Asp205) are the main contributors for the binding (figs. 3.5
and 3.13A). Although the ring scaffold was slightly rotated, its position based on the
anchored hydroxyl group (by Asp205 and Arg410) in D-ring, the hydrogen bond between
Ser247 and hydroxyl group in A-ring were retained during the simulation. Superposition of
the docking results are shown in fig. 3.13B.
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AB
Figure 3.13: A: binding mode of E01 (17 -estradiol) to the PXR in stereo view. The ligand has been
completed with hydrogens. The protein is represented as cartoon, key amini-acid residues and the
ligand as sticks. B: the Docking results for E01–E08. The carbon atoms of the ligands are colored in
green.
T02–T12 are derivative compounds of T01 (T091317). The template structure engages two
hydrogen bonds with Gln285 and His407, the sulfonyl-benzyl group is stabilized through
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the hydrophobic pocket formed by Phe288-Trp299-Tyr306. These interactions are retained
for all derivative compounds as shown in fig. 3.14.
A
B
Figure 3.14: A: binding mode of T01 (T091317) to the PXR in stereo view. The ligand has been
completed with hydrogens. The protein is represented as cartoon, key amini-acid residues and the
ligand as sticks. B: the Docking results for T01–T12. The carbon atoms of the ligands are colored in
green.
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Similarly to T091317, 2Q4 also features hydrogen-bond interactions with Gln285 and
His407, as well as hydrophobic interactions towards the Phe288-Trp299- Tyr306 pocket.
The superposed docking results of S02–S25 are shown in fig. 3.15.
A
B
Figure 3.15: A: bindingmode of S01 (2Q4) to the PXR in stereo view. The ligand has been completed
with hydrogens. The protein is represented as cartoon, key amini-acid residues and the ligand as
sticks. B: the Docking results for S01–S25. The carbon atoms of the ligands are colored in green.
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Ensemble docking andMD simulation
For compounds lacking a similar ligand in the PDB bound to the PXR, automated docking
approaches (AutoDock/Cheetah, Schrödinger’s QPLD and IFD) were performed to sample
and rank the potential binding modes for the representative ligands in each class
(A01–A18, P01–P23,M01–M07, B01–B09). Then the ligand conformations compiled from
the first step on were used as boundary criteria for the selection of potential binding
mode(s), hydrogen bonds with crucial residues (Gln285, His407, Ser247, Asp205 and
Arg410) and hydrophobic interactions with the Phe288–Trp299–Tyr306 pocket were
considered as key factors to select the most realistic binding mode(s). The kinetic stability
for the selected binding modes was challenged by MD simulations. Finally, the identified
stable binding mode(s) of the representative compounds were used as templates for their
respect derivate ligands and interactively docked with YetiX.
A: Case Study 1—Docking of 5 -androstan-3 -ol-17-one (steroid)
For the steroid compounds, the top-ranked poses as generated by Schrödinger’s IFD
mainly occupy the hydrophobic pocket defined by Phe288–Trp299–Tyr306. However,
17 -estradiol does not occupy this pocket (PXE2), it features hydrogen bonds with Asp205,
Ser247 and Arg410. Such interactions were not observed in any of the IFD poses. These
results suggest that although the IFD protocol trends to yield high-ranking order for
hydrophobic interactions, it is not truly suitable for generating and ranking poses in which
the hydrogen-bond interactions play a central role for the binding, such as steroids to the
PXR. On the other hand, the automatic docking protocol implemented in Cheetah, which
employs a directional force field, combined with a template-based alignment protocol,
showed a top-ranking order for the pose similar to the crystal structure. For example,
5 -androstan-3 -ol-17-one, which displays a appreciable binding affinity toward the PXR
(EC50=20.0nM), the top-ranked binding pose shows good agreement (RMS= ) compared
with its template 17 -estradiol. The androstan is stabilized by generating hydrogen bond
with Asp205 and Arg410. The kinetic stability of the binding pose was challenged by
means of a 10.0 ns MD simulation. The ligand remained in its original position and
orientation, and the hydrogen bonds with Gln285 and Asp205 were retained. As the
hydrophilic part in some of the ligands are missing, top-ranked docking poses with both
programs were accepted for template-based docking in order to consider both
hydrophobic interactions and hydrogen bonds.
51
A Docking pose B The last MD frame
Figure 3.16: Ligand binding of 5 -androstan-3 -ol-17-one to the PXR.
A01–A04 contain a L-shaped ring conformation (ring A and ring B are linked in
cis-conformation) and two types of binding modes were identified from the docking
results (fig. 3.17). In the first type (fig. 3.17A), His407 and Arg410 could act as
hydrogen-bond donor for the ligands; In the second type (fig. 3.17B), the 3-hydroxyl group
is stabilized by engaging hydrogen bonds with Asp205 and Arg410, the 17-carbonyl group
engaged a hydrogen bond with Gln285.
A B
Figure 3.17: Docking results for A01–A04.
A05–A18 contain a flat 6-6-6-5 ring conformation (ring A and ring B are in
52
trans-conformation) and mainly contain four types of binding modes depending on their
respect hydrophilic functional groups in each compound (fig. 3.18). The first and second
types (fig. 3.18 A and B) are similar to the two binding modes of 17 -estradiol, which
features hydrogen bonds towards Ser247, Asp205 and Arg410. The third and fourth types
contain only one hydrogen bond towards Ser247 and His410 respectively, unlike type A
and B, they also engage hydrophobic interactions towards the Phe288- Trp299-Tyr306
pocket.
A B
C D
Figure 3.18: Docking results for A05–A18.
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Ring A and ring B in P01–P08 are in cis conformation, two types of binding modes are
considered. Type A (fig. 3.19A) features hydrophobic interactions towards the
Phe288-Trp299-Tyr305 pocket and a hydrogen bond with His407; type B (fig. 3.19B) mainly
engages hydrogen bonds towards Gln285, Asp205 and Arg410. For P09–P23, ring A and
ring B are in trans-conformation, the binding modes are familiar with type A ligands
(fig. 3.19C and D), except that type D is less convergent than type B.
A B
C D
Figure 3.19: Docking results for P01–P23.
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B: Case Study 2—Docking for M01
M01 is a high-affinity PXR agonist (EC50 =0.7 nM) which contains two aromatic ring, the
reported putative bindingmodewas generated bymimicking the bindingmode of T091317
(PDB: 2O9I).49
Figure 3.20: A: ligand binding site of T091317, B: T091317 and M01. highlighted are the similar
fragments.
In the crystal structure, the benzyl-sulfonamide group was found binding to the
hydrophobic pocket Phe288–Trp299–Tyr306, forming face-face ⇡-⇡ stacking with Phe288
and T-shaped ⇡-⇡ stacking with Trp299. The sulfonyl group was further stabilized by
engaging a hydrogen bond with Gln285. However, the five methyl substituted aromatic
ring inM26 prevents a similar pose due to steric hindrance. Docking both by Cheetah and
IFD were performed to generate putative binding modes. Top-ranked poses in both
protocol were interactively inspected, four poses identified from Cheetah and three from
IFD were selected and the kinetic stability were challenge by MD simulations with the
AMBER package.
Ligand RMSD values were recorded for the 10 ns production-phase for each of the selected
poses (fig. 3.21). The Cheetah docking poses were all above 2 Å, which suggest that the
thermodynamic identified conformation is kinetically not stable. On the other hand, two
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poses generated by IFD yielded low RMSDs (around 1 Å), which indicate a higher kinetic
stability. For these two trajectories, a more detailed analysis was performed: the start/end
state conformations, key hydrogen-bond distances and per-residue binding energy were
recorded.
A
B
C
D
Figure 3.21: A and B: Ligand RMSD of MD simulation for PXR-M26 binding poses generated by
Cheetah (A) and IFD (B); C: H-bond distance of pose 1 (left) and pose 2 (right); D: Binding energy
decomposition by MM-PBSA of IFD pose 1 (left) and pose 2 (right).
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Figure 3.22: Bindingmodes before and afterMD. (A) IFD pose 1 beforeMD, (B) IFD pose 1 afterMD,
(C) IFD pose 2 before MD, (D) IFD pose 2 after MD.
Pose 1 and 2 share a common binding pattern toward the F288–W299-Y306 pocket, as well
as the hydrogen bonds to His327 and Gln285, this interaction pattern is conserved during
the 10 nsMD simulations. The benzimidazole ring in pose 2 is further stabilized by forming
hydrogen bond with His407, which locked the flexibility of the benzimidazole ring as in
pose 1 it ismore flexible than pose 2. The IFD protocol performed better results for docking
ligands with aromatic/hydrophobic moieties. The empirical scoring function is trained for
pattern recognition, which has benefits for the recognition of ⇡-⇡ stacking. Bindingmodes
for the derivative compounds of M01 (M02–M09) were docked to the PXR based on the
stable IFD poses by interactive docking with Yeti.
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For S01–S07, Gln285 act as hydrogen-bond donor for the binding, The hydrophic pocket
Phe288–Trp299–Tyr306 could either engage hydrophobic interactions with the aromatic
ring or cyclobutane of the ligands, identified binding poses are shown in fig. 3.23. Finally,
top-ranked poses generated by Cheetah are also included as augment for the QSAR
study.
A B
C
Figure 3.23: Stereo view of three kinds of binding modes for S01–S07 to the PXR.
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3.2.5 Multidimensional QSAR for the PXR
The ligand data from the docking poses were combined as input for the quantitative
structure-activity relationship software Quasar, including ligand-specific information: its
free energy of ligand binding ( Gexp, converted from EC50 data), ligand-desolvation
energy, loss of entropy (T S) upon ligand binding as well as the increase of ligand-internal
energy (strain) when binding from an aqueous environment to a hydrophobic receptor
typically hydrophobic in nature.
In theQuasar simulation, the model family of the PXR (fig. 3.24 and table 3.1) converged at
cross-validated r2 of 0.812 for the73 training compounds leavingone thirdof the set out, and
yielded a predictive r2 of 0.854 for the 24 test ligands. The average deviation (rms) between
experimental and calculated affinities is of a factor of 2.0 for the training and 1.3 for the test
set. The maximal deviation in the prediction of binding affinities for a compound is of a
factor of 22.3 for training set and 4.7 for the test set, respectively.
When compared to the crystal structure of the PXR complexed with the two ligands, the
receptor surrogate generated by Quasar properly reproduces properties observed for the
amino-acid residues in the binding pocket: two hydrogen bond donors (big|yellow) are
located close to the position occupied by Ser247 and Arg410, and two hydrogen bond
acceptor (big|blue) are located close to the position occupied by Asn205 and Gln285.
Moreover, hydrophobic properties (gray and brown) populate great part of the surface,
correctly reflecting the hydrophobic character of the binding pocket.
To challenge the model, a second software (Raptor) — using the same ligand alignment
and selection — was applied to yield an r2 of 0.870 and a predictive r2 of 0.646. When
compared with Quasar, the Raptor simulation would only seem to yield a modest
predictive power. Considering the limited range of experimental activity (77% of
compounds cluster within two orders of magnitude), the compound’s chemical diversity
and the different literature source for the affinities, the Raptor model can be considered
acceptable in terms of quality.
A representation of the receptor surrogate with bound the compound 17 -estradiol and
T091317 is depicted in fig. 3.24.
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A B
C D
Figure 3.24: A: Representation of the Quasar model of PXR surrogate (Quasar) with bound
compound 17 -estradiol and T091317(space-filling). The mapped quasi-atomistic properties are
sized|colored as follows: big|blue (H-bond donor), big|yellow (H-bond acceptor), middle|saddle
brown (hydrophobic, positively charged), middle|chocolate brown (hydrophobic, negatively
charged), tiny|grey (hydrophobic, neutral), tiny|blue (solventwater). B: Comparisonof experimental
andpredictedbinding affinities of the training set (blue circles) and test set (red triangles) for thePXR
by Quasar. C: Raptor model of the PXR with bound 17 -estradiol and T091317. D: Comparison
of experimental and predicted binding affinities of the training set (blue circles) and test set (red
triangles) for the PXR by Raptor.
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Table 3.1: Summary of the Quasar and Raptor simulations for the 73 training and 24 test
compounds
Simulation r2 q2 rms. training max. training p2 rms. test max. test
Quasar 0.812 0.815 2.0 22.3 0.854 1.3 4.7
Raptor 0.870 n/a 0.9 3.9 0.646 3.8 16.8
r2: correlation coefficient, q2: cross-validated r2, p2: predictive r2; the rms and maximal
deviation from the experimental binding affinity is given as a factor (off) in Ki.
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3.3 In silico evaluation of anti-trypanosome natural
products
The binding of natural products, potentially active against the Human African Trypano-
somiasis (HAT), towards 16 off-targets was simulated and quantified by means of the
VirtualToxLab.38 For each of the binding affinities computed below 100 nM, a subsequent
5.0–10.0 ns MD simulation was performed to probe the kinetic stability of the
protein–ligand complex. Table 3.2 shows the selected compounds with their respective
targets. In the following section, the underlying bindingmodes and affinities are discussed
in detail.
Table 3.2: Active compounds towards selected targets as identified by the VirtualToxLab
Target Compound(s)
16 27 70 (S)-71
Androgen
receptor
72 85 91 93
97 98 100
Aryl
hydrocarbon
receptor
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Estrogen
receptor  
92 98
Glucocorticoid
receptor
(S)-71 85 88 89
Mineralocorti-
coid receptor
(R)-71 72 98
Progesterone
receptor
33 34 39 (S)-71
74 (R)-76 77 85
Thyroid
receptor  
85
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CYP450 2D6
37 80 88
3.3.1 Compounds active towards the androgen receptor
Eleven compounds were identified as active towards the AR by the VirtualToxLab, of
which two are sesquiterpene lactones 16 and 27 (with computed IC50 values of 31.4 nM
and 19.3 nM respectively); three are psoralen derivatives 70 (88.1 nM), (S)-71 (35.4 nM)
and 72 (25.7 nM); and three are paprazine derivatives 97 (22.9 nM), 98 (6.49 nM) and 100
(92.0 nM).
For 16 and 27: the docking poses contributing most to the binding affinity are quite
different (fig. 3.25). Although they both engage in hydrogen bonds with Asn705 and
Thr877, 16 donates its hydroxyl group from the 7-membered ring while 27 provides it from
its allyl-alcohol side chain—which is more flexible. In addition, 27 is further stabilized by
Met745 and Arg752. After challenging the docking (input structure: thermodynamic
lowest-energy pose) by means of 5 ns MD simulation each, the ligand movement was
analyzed by recording the RMSD of the heavy atoms on its rings. The position and
orientation of 16 became stable after 4 ns production run when its RMSD was fluctuated
around 0.5 Å, which indicating that the docking pose of 16 with the AR is unfavorable due
to ligand flexibility. In contrast hereto, the RMSD of 27 remained around 0.5 Å for the
whole production phase. The moderate movement during the equilibration stage is
probably due to receptor adaption (induced fit including the main chain) and interactions
with the surrounding water molecules.
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Figure3.25: Topandmiddle: Details of the binding of16 (top) and27 (middle) to theAR. The ligands
are represented as licorice, key amino-acid residues as balls and sticks, hydrophobic residues within
the binding pocket as surface colored in yellow. Carbon, nitrogen, oxygen and hydrogen atoms are
colored in black, blue, red and white respectively. Bottom: Ligand RMSD during theMD simulation
for 16 (left) and 27 (right), negative values in the x-axis refer to the equilibration stage.
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The binding energies were obtained by the MM-PBSA protocol (fig. 3.26). 16 lost its
hydrogen bond with Asn705 during the simulation while the interaction with Thr877 was
retained, the ligand is further stabilized mainly by the hydrophobic residues Leu704 and
Leu873. 27 lost its hydrogen bonds with Arg752 and Thr877, in contrast, the hydrogen
bonds with Asn705 or Met745 were retained, the ligand is further stabilized mainly by
Phe764, Met780 and Leu873.
A
B
Figure 3.26: Binding-energy decompositionwithin the binding pocket and time-resolved details for
key amino-acid residues with respect of 16 (a) and 27 (b) binding to the AR.
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For the psoralen derivatives—70, (S)-71 and 72: the docking poses contributing most to
the binding affinity are quite similar (fig. 3.27), which indicates that the interactions are
conservative in nature. Asn705 and Thr877 generated bridging hydrogen bonds to all three
ligands; 70 and 72 formed a third hydrogen bond with Gln711.
Figure 3.27: Details of the binding of 70 (top), (S)-71 (middle) and 72 (bottom) to the AR.
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The ligand RMSDs (of the ring heavy atoms) and the hydrogen-bond distances are shown
in fig. 3.28. The RMSDs remained below 1.5 Å within 8 ns of the production stage
compared with the initial frame for all the three ligands. The hydrogen bond between
(S)-71 and Gln711 became stable only after 5 ns, all the other hydrogen bonds remained
stable throughout the simulation (Gln711 could flip the symmetrically related HN21 and
HN22 during the MD simulation; consequently, the shorter of the two was recorded),
except for 70, which lost the interaction with Thr877 after 2 ns of the production
stage.
Figure3.28: The ligandcoreRMSDs (aromatic ringatoms) are shownon the left panel, thehydrogen-
bond distances are shown on the right. The complexes of 70, (S)-71 and 72with the AR are arranged
at the top, middle and bottom, respectively.
MM-PBSA energy (fig. 3.29): the free-energy contribution of Asn705 towards (S)-71 and 72
are retained; the free-energy contribution of Gln711 towards S)-71 and 73 are retained
throughout the MD simulation, while for 72 it is retained after 5ns production, which is in
agreement with the trends of hydrogen-bond distance; the free-energy contribution of
Thr877 towards all three ligands are retained throughout the simulation. In addition, 70 is
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further stabilized mainly by Leu704, Arg752 and Leu873 within the binding pocket; (S)-71
is further stabilized mainly by Leu704 and Met745; 72 is further stabilized mainly by
Leu704, Arg780 and Leu873.
A
B
C
Figure 3.29: Binding-energy decompositionwithin the binding pocket and time-resolved details for
key amino-acid residues with respect of 70 (a), (S)-71 (b) and 72 (c) binding to the AR.
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For the paprazine compounds—97, 98 and 100: the thermodynamic poses contributing
most to their respective affinity are displayed in fig. 3.30. They all feature hydrogen bonds
with Asn705 and Thr877; in addition, for the complex of the AR and 100, the amide group
is stabilized by Gln711.
Figure 3.30: Details of the binding of 97 (top), 98 (middle) and 100 (bottom) to the AR.
70
The ligand RMSDs for 97 and 98 increased above 3.0 Å compared with their docking poses,
whichmeans they would not be kinetically stable; for 100 the ligand RMSD remains within
1.5 Å compared with both the thermodynamic lowest-energy pose and the last MD frame
(fig. 3.31A). The hydrogen-bond distances of 100 with Asn705, Gln711 and Thr877 are
within 2.0 Å during most of the production stage, which implies that these three residues
continuously stabilize the ligand (fig. 3.31B). MM-PBSA calculation (fig. 3.31C) also
suggest the free-energy contributions of Asn705, Gln711 and Thr877 to 100 remains stable
during the whole simulation.
A
B
C
Figure 3.31: a: Ligand RMSDs of the AR with 97 (left), 98 (middle) and 100 (right). b: key-residue
hydrogen-bond distances for the complex of AR and 100. c: Binding-free energy contributions
within the binding pocket and time-resolved details for key amino-acid residues of the AR binding
with 100.
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The docking poses of 85 or 93 with the AR did not remain stable according to high ligand
RMSDs (fig. 3.32A); for 91, though the ligand RMSD was mainly below 1.5 Å, the hydrogen
bonds generated by 91 with Asn705 and Thr877 were not retained during the simulation,
instead the ligand formed an intra-molecular hydrogen bond, which does not contribute to
the binding affinity (fig. 3.32B).
A
B
Figure 3.32: a: Ligand RMSD of 85 (left), 91 (center) and 93 (right) with the AR; b: detail of the
docking mode of 91 (up) and the AR and the last MD frame (down).
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3.3.2 The only compound active towards the Aryl hydrocarbon
eceptor
Tanshinone IIA (54) was identified as the only compound active towards the AhR, with a
computed IC50 of 26 nM. The docking pose contributing most to the binding affinity (as
identified by theVirtualToxLab: thermodynamic solution) and the corresponding structure
toward the end of 5.0 ns MD simulation (kinetic solution) are shown in fig. 3.33.
Figure 3.33: Details of the binding of tanshinone IIA to the AhR as identified by the VirtualToxLab
(top) and the last MD frame (bottom).
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In the binding pocket, tanshinone IIA is accommodated by the hydrophobic residues Phe4,
Phe12, Pro14, Leu25, Leu32, Phe41, Ile42,Met57, Phe68, Leu70, Ala84 andVal98. The ligand
is further stabilized by engaging a hydrogen bond with the side-chain hydroxyl group of
Ser82, whichwas retained throughout the entire simulationperiod. An additional hydrogen
bond with the side-chain amide group of Gln100 surfaced after the equilibration step and
remained stable thereafter. The system turned out to be stable after 1.3 ns, where the RMSD
was reduced to 1 Å compared with the last MD frame. During the whole 5.0 ns production
phase, the ligandRMSDremainedbelow1.0Å comparedwith the last frame,which suggests
that the equilibrated pose was stable during the whole production stage (fig. 3.34A). The
MM-PBSA results (fig. 3.34B) also confirmed the stable free-energy contributions of Ser82
and Gln100, and further suggest that Ile42 plays an important role for the binding.
A
B
Figure 3.34: a: Time-resolved details of ligand RMSD and key-residue hydrogen-bond distances
of 54 binding to the AhR. b: Binding-energy decomposition within the binding pocket and time-
resolved details for key amino-acid residues of the AhR binding with 54.
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3.3.3 Compounds active towards the estrogen receptor  
Abruquinone I (92) and moupinamide (98) were predicted to be active towards the ER ,
with computed IC50 of 78.2 nM and 24.8 nM respectively. After challenging the docking
poses contributing most to the affinities (as identified by the VirtualToxLab) by means of
10 ns MD simulations, abruquinone I slightly changed its binding while moupinamide
underwent a substantial movement as illustrated in fig. 3.35, indicating that the
thermodynamically identified docking pose of moupinamide is not favorable.
Figure 3.35: Ligand RMSD of 92 (left) and 98 (right) binding to the ER .
For the docking pose of abruquinone I to the ER , the ligand is stabilized by a hydrogen
bond with Glu305. The negatively charged Glu305 forms a salt bridge with the positively
charged Arg346. After the MD simulation, the ligand scaffold retains at its original shape.
The hydrogen-bond stabilization of the ligand shifted to the backbone of Leu339
(fig. 3.37A). As depicted in fig. 3.36, the hydrogen bond generated between the ligand and
the ER  was engaged in a conjugated switch between Glu305 and Leu339. The MM-PBSA
result also suggest Leu339 retains free-energy contribution to the binding towards
abruquinone I (fig. 3.37B).
Figure 3.36: Hydrogen bond distances of abruquinone I binding to the ER .
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AB
Figure 3.37: a: Details of the binding of 92 to the ER  as identified by the VirtualToxLab (top) and
the last MD frame (bottom). b: Binding-energy decomposition within the binding pocket and time-
resolved details for key amino-acid residues of the ER  binding with 92.
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3.3.4 Compounds active towards the glucocorticoid receptor
S-71, 85, 88 and 89were predicted to be active towards the GR, with computed IC50 of 45.8
nM, 68.1 nM, 19.7 nM and 87.2 nM respectively. For S-71, 85 and 88, the thermodynamic
poses contributing most to their respective affinity are displayed in fig. 3.39. They all
feature hydrogen bonds with Asn564 and Gln570, in addition, 85 and 88 are also stabilized
by engaging a hydrogen bond with Gln642. After challenging the docking by 10 ns MD
simulation, the RMSD of 89 increased to 4 Å compared with its starting pose, indicating a
large movement, while the other ligands remain stable throughout the production phase
and showed only a moderate movement during the equilibration stage (fig. 3.38A). The
hydrogen-bond distances between Asn564 and all three ligands are retained during the
simulation; only the hydrogen-bond distance between Gln570 and 88 is retained; for 88
and 89, the ligand is further continuously stabilized by Cys638 and Gln642 respectively
(fig. 3.38B).
A
B
Figure 3.38: a: Ligand RMSD of S-71 (top left), 85 (top right), 88 (bottom left) and 89 (bottom right)
binding to the GR. b: Time-series key-residue hydrogen-bond distances for S-71 (left), 85 (middle)
and 88 (right) binding to the GR.
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Figure 3.39: Details of the binding of S-71 (top), 85 (middle) and 88 (bottom) to the GR.
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The MM-PBSA results further suggest the agreement with the time-series hydrogen- bond
distance results (fig. 3.42): the free-energy contribution of Asn564 to all three ligands are
retained; the contribution of Gln570 is retained for 71 and 85; the contribution of Cys638 to
85 is retained after 5.0 ns and the contribution of Gln642 is retained for 88 throughout the
MD simulation.
A
B
C
Figure 3.40: Binding-energy decompositionwithin the binding pocket and time-resolved details for
key amino-acid residues with respect of (S)-71 (a), 85 (b) and 88 (c) binding to the GR.
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3.3.5 Compounds active towards themineralocorticoid receptor
Figure 3.41: Top: Ligand RMSD of R-71, 72, and 98 with the MR; middle: details of the binding of
71Swith the MR; bottom: details of the binding of 72 to the MR.
R-71, 72 and 98 are predicted to be active towards the MR, with computed IC50 of 73.4 nM,
84.8 nM and 15.0 nM respectively. After challenging the docking poses contributing most
to the affinities (as identified by the VirtualToxLab) by means of 10 ns MD simulations, the
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ligand RMSDs of R-71 and 72 remained below 1.5 Å, while the ligand RMSD of 98 increased
to 3 Å during the equilibration stage, indicating that the conformations of R-71 and 72 are
kinetically stable to the MR. The hydrogen bond distances between Gln776 with and the
ligands are retained during the simulation (fig. 3.42). MM-PBSA results further suggest that
the binding free energy of Gln776 is retained for both (R)-71 and 72.
A
B
C
Figure 3.42: a: Hydrogen-bonddistance of Gln776with (R)-71 (left) and 72 (right). b and c: Binding-
energy decomposition within the binding pocket and time-resolved details for key amino-acid
residues as respect of (R)-71 (b) and 72 (c) binding to the MR.
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3.3.6 Compounds active towards the progesterone receptor
33, 34, 39, (S)-71, 74, (R)-76, 77, and 85 are predicted to be active towards the PR, with
computed IC50 values of 3.69 nM, 19.7 nM, 35.0 nM, 98.6 nM, 69.2 nM, 56.2 nM, 27.3 nM
and 32.2 nM, respectively.
The docking poses of 33 and 34 contributing most to their respect binding affinities are
quite similar (fig. 3.43). 33 features hydrogen bonds with both Arg766 and Thr894 while 34
engages only a hydrogen bond with Arg766 only.
Figure 3.43: Details of the binding of 33 and 34 to the PR.
After challenging the binding by a 5.0 ns MD simulation: the ligand RMSDs are within 2.0
Å for both compounds (fig. 3.44A); the hydrogen-bond distances between Arg766 and the
two ligands are retained at approximately 2.4 Å, while the hydrogen-bond between Thr894
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and the ligands are not retained (fig. 3.44B). The MM-PBSA results (figs. 3.44C and 3.44D)
further suggest that Arg766 provides stable free-energy contributions for 33 and 34 during
the MD simulation.
A
B
C
D
Figure 3.44: a: Ligand RMSD of 33 and 34 to the PR. b: key-residue hydrogen-bond distances of
33 and 34 to the PR. c and d: Binding-energy decomposition within the binding pocket and time-
resolved details for key amino-acid residues of the PR binding with 33 (c) and 34 (d).
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39 is stabilized by engaging hydrogen bonds with Leu718, Gln725 and Cys891 while 85 is
stabilized by Gln776, Arg817 andMet852, respectively (fig. 3.45).
Figure 3.45: Details of the binding of 39 and 85 to the PR.
After challenging the binding by a 5.0 nsMD simulation: the ligand RMSDs are within 2.0 Å
for both ligands (fig. 3.46A); the hydrogen-bonddistance betweenLeu718 and 39 is retained
at approximately 2.5 Å, the hydrogen-bond between Arg817 and 85 is kept at approximately
2.3 Å (fig. 3.46B), the other hydrogen bonds are not retained after MD simulation. MM-
PBSA results (figs. 3.46Cand3.46D) further suggest that Arg766 features anunfavorable  G
contribution for 33, the   G fluctuation of Arg766 toward 85 is quite high, which suggests
that these two poses are less likely kinetically stable.
84
AB
C
D
Figure 3.46: a: Ligand RMSD of 39 and 85 to the PR. b: key-residue hydrogen-bond distances of
39 and 85 to the PR. c and d: Binding-energy decomposition within the binding pocket and time-
resolved details for key amino-acid residues of the PR binding with 39 (c) and 85 (d).
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For (S)-71, 74, (R)-76 and 77, the docking poses contributing most to the binding affinity
are quite similar, which indicates that the interactions are conservative in the nature. The
compounds are all stabilized by engaging a hydrogen bond with Arg766. After challenging
the binding by 5 ns ofMD simulation: the ligand RMSDs are within 2.0 Å, and the hydrogen
bond is retained for all the poses.
A
B
Figure 3.47: a: Details of the binding of (S)-71 (top left), 74 (top right), (R)-76 (bottom left) and 77
(bottom right) to the PR. b: Ligand RMSD (left) and key-residue hydrogen-bond distances (right) to
the PR, from top to bottom: (S)-71, 74, (R)-76 and 77.
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The MM-PBSA results further suggest the free-energy contribution within the binding
pocket is similar for all the four ligands. Arg766 substantially contributes to the major   G
throughout the MD simulation for all ligands. Furthermore, Leu718 is another major
contributor for   Gmainly due to hydrophobic interactions.
Figure 3.48: Binding-energy decompositionwithin the binding pocket and time-resolved details for
key amino-acid residues, from top to bottom: (S)-71, 74, (R)-76 and 77.
87
3.3.7 The only compound active toward the thyroid receptor  
From the VirtualToxLab screening, alisol A (85) was identified as active towards the
TR  (computed IC50 value = 33.5 nM). The docking pose contributing most to the binding
affinity is shown in fig. 3.49. The hydrophobic skeleton (6-6-6-5 ring system) is stabilized
by the hydrophobic residues lining in the binding pocket. Alisol A is further stabilized by
engaging a hydrogen bond with Arg282.
Figure 3.49: Details of the binding of 85 to the TR  by theVirtualToxLab (top) and the lastMD frame
(bottom).
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After challenging the binding by means of 5.0 ns MD simulation, the ligand RMSD is
within 2.0 Å compared with the first frame (fig. 3.50A). Aside from Arg282, the three
adjacent hydroxyl group further engaged stable hydrogen bonds with Arg306 and Asn331,
the bond distances are retained throughout the MD simulation (figs. 3.49 and 3.50B). The
MM-PBSA results (fig. 3.50C): Arg282, Arg316 and Asn332 would seem to be the major
contributors for the binding, as well as Met313 and His435 also yield favorable
contributions mainly due to hydrophobic interactions.
A
B
C
Figure 3.50: a: Ligand RMSD relative to the first and the last simulation frame. b: Hydrogen-bond
distances of Arg282, Lys306 and Asn331 with alisol A. c: Binding-energy decomposition within the
binding pocket and time-resolved details for key amino-acid residues for 85 to the TR .
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3.3.8 Compounds active toward the Cytochrome P450 2D6
37, 80 and 88 were identified as active towards the CYP2D6, with computed IC50 values of
12.6 nM, 7.86 nM and 3.61 nM, respectively. The docking pose contributing most to the
binding affinity is shown in fig. 3.51.
Figure 3.51: Details of the binding of 37, 80 and 88 to the CYP2D6.
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Figure 3.52: Binding-energy decompositionwithin the binding pocket and time-resolved details for
key amino-acid residues for 37 (a), 80 (b) and 88 (c) to the CYP2D6.
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Chapter 4
Conclusions
Employing a genetic algorithm, a 4D scoring function based on a total of 1,288
compounds binding to 16 different proteins (enzymes, receptors, ion channels) has been
developed and compared against existing concepts. In the new function, the interaction
ligand–protein energies are decomposed into electrostatic, van der Waals, hydrogen
bonding and polarization components, which allows for a direct estimation of the
associated binding affinity. This algorithm can be employed in consensus-scoring mode
to existing concepts for the prediction of binding affinities based on three-dimensional
ligand–protein structures. Current limitations of the scoring function include larger
induced-fit movements and, if present, substantial entropic contribution of solvent
released upon ligand binding.
Using the Quasar software, a QSAR model for the pregnane X receptor (PXR) was
developed and validated. The binding modes of the individual compounds were either
obtained from a crystal structure or, when absent, identified by interactive docking,
followed by extensive molecular-dynamics simulations. These poses were subsequently
employed as templates for the flexible docking of 101 compounds (comprising eight
chemical classes) and the generation of the final model. It converged at a cross-validated
r2 of 0.812 (for 72 training compounds) and yielded a predictive r2 of 0.854 (for 29 test
compounds). Consensus scoring with the Raptor software yielded corresponding values of
0.870 and 0.646, respectively. This suggests that the models can be applied to predict the
binding affinity of novel drug candidates towards the PXR, which will be extremely
valuable in the early stages of the drug-discovery process. At the molecular level, residues
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Asn205, His247, Gln285, His407 and Arg410 would seem to play a key role for stabilizing
potential ligand molecules trough hydrogen bonds. Hydrophobic stabilization of the
ligand–protein complex, on the other hand, is mainly achieved through the residues
Phe288, Trp299 and Tyr306. Limitations of the models involve the applicability domain,
which does only include neutral species. The availability of high-quality experimental
data turned out to be a limiting factor for the choice of a larger dataset. The application of
interactive docking is not adequate for high-throughput screening, where automated
procedures are necessary. Further improvement of the automated docking process could
be achieved by implementation of knowledge-based rules. In summary, this model
represents a basis for a future extension of the VirtualToxLab — an in silico tool for
predicting side effects and toxicity of drugs, chemicals and natural compounds.
Potential side effects and toxicity of anti-trypanosomiasic active compounds were
investigated using the VirtualToxLab. This technology identifies the binding mode of a
small-molecule compound toward a series of 16 target proteins (nuclear receptors,
cytochrome P450 enzymes, hERG, AhR) known or suspected to trigger adverse effects. As
this technology provides thermodynamic information only, all relevant ligand–protein
complexes were challenged by subsequent molecular-dynamics simulations.
Sesquiterpene lactones showed a potential affinity toward the androgen, glucocorticoid
and the mineralocorticoid receptor. Tanshinone and its derivatives displayed an affinity
toward the aryl-hydrocarbon and the thyroid receptor  . Alisol A and its derivatives bind to
the androgen and the glucocorticoid receptor. Smyrniorin and its derivatives showed a
substantial affinity toward the glucocorticoid, mineralocorticoid and the progesterone
receptor. Isoflavan showed a high affinity toward the thyroid receptor  . This protocol
would seem to be a promising approach for probing the interactions of ligands with
relevant target proteins.
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Appendix A
Chemical structure of the PXR ligands
A.1 Chemical structures
A.1.1 Estratrienes (E01–E08)
94
A.1.2 Androstans (A01–A18)
95
A.1.3 Pregnanes (P01–P23)
96
A.1.4 T091317 derivatives (T01–T12)
A.1.5 BMS-817399 derivatives (S01–S07)
97
A.1.6 Benzenesulfonamide derivatives (M01–M09)
A.1.7 2-Aryl indoles (N01–N08)
98
A.1.8 Substituted phenyl triazoles (G01–G16)
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Appendix B
Anti-trypanosomal compounds
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